Owen Roger G
HMDS Laboratory, The General Infirmary at Leeds, Leeds, UK.
Semin Oncol. 2003 Apr;30(2):196-200. doi: 10.1053/sonc.2003.50069.
Waldenstrom's macroglobulinemia (WM) is a poorly characterized B-cell lymphoproliferative disorder. There are a relatively limited number of detailed clinicopathological assessments, while the majority of clinical trials have been nonrandomized, single-institution phase II studies. Unfortunately progress in this disorder has been hindered by a lack of universally accepted diagnostic criteria. It is clear that criteria incorporating clinical, morphological, immunophenotypic, and, ultimately, genotypic parameters are needed for future clinical trails. Following a detailed clinicopathological assessment of 111 patients and a review of the published literature the following diagnostic criteria were proposed for WM: IgM monoclonal gammopathy of any concentration, bone marrow infiltration by small lymphocytes, plasmacytoid cells and plasma cells in a diffuse, interstitial or nodular pattern, and a surface Ig(+)CD19(+)CD20(+)CD5(-)CD10(-)CD23(-) immunophenotype.
华氏巨球蛋白血症（WM）是一种特征描述不足的B细胞淋巴增殖性疾病。详细的临床病理评估数量相对有限，而大多数临床试验都是非随机的单机构II期研究。不幸的是，该疾病的进展因缺乏普遍接受的诊断标准而受阻。显然，未来的临床试验需要纳入临床、形态学、免疫表型以及最终基因型参数的标准。在对111例患者进行详细的临床病理评估并回顾已发表的文献后，提出了以下WM诊断标准：任何浓度的IgM单克隆丙种球蛋白病、小淋巴细胞、浆细胞样细胞和浆细胞以弥漫性、间质性或结节性模式浸润骨髓，以及表面Ig(+) CD19(+) CD20(+) CD5(-) CD10(-) CD23(-)免疫表型。
